INFLUX

Current scenario: - Revenue from operations stood at INR85.4 crores in H1 FY27, registering a 27.9% YoY growth. - EBITDA stood at INR18.3 crores, up by 25.2% YoY with margins at a healthy 21.5% (moderated by 50 bps). - PAT stood at INR12 crores, up 20% YoY with margins at 14.1%. - Client base stands at 500+ with a retention rate of 88% and product portfolio expanded to over 2,300 SKUs. Changes in trends: - Inventory days increased from 99 to 124 days due to higher demand and accumulated orders. - Trimming smaller clients to focus on operational efficiency and larger customers. Management Guidance & Outlook: - Company anticipates a growth target of 25% for FY27 backed by consistent profitability margins. - Targeting revenue of INR450-500 crores in the next 2-3 years (FY28-29) upon full utilization of expanded capacity. Capex: - Incurred INR19.9 crores in H1 FY27 towards PPE and intangible assets. - New 75,000 sq. ft. manufacturing facility civil work is complete; internal partition and flooring ongoing with expected operations starting by December/January. Growth Drivers: - Capacity expansion (2.5x machinery capacity increase in the new facility). - New product lines including multi-layer wafer bars, RTD blister shot machines, Quick Snap format, and pet nutrition extrusion lines. - International expansion with ongoing product registrations in Tanzania, Nigeria, and Kenya.